HENDERSON, Nev.--(BUSINESS WIRE)--May 3, 2018--
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company
with fully integrated commercial and drug development operations with a
primary focus in hematology and oncology, announced today an exclusive
licensing agreement with The University of Texas MD Anderson Cancer
Center for intellectual property related to certain methods of use of
poziotinib.
“We have been aggressively pursuing the potential of exon 20 mutations
and treatment with poziotinib since the inception of our relationship
with MD Anderson, but we’ve both only begun to scratch the surface of
the science and poziotinib’s potential as a targeted treatment for
various solid tumors,” said Joe Turgeon, president and CEO of Spectrum
Pharmaceuticals. “Late-stage poziotinib clinical data targeting the exon
20 mutations are promising, and we are thrilled to enter this new
agreement that strengthens and potentially extends our patent protection
until 2037 as we continue this journey of discovery together.”
“Dr. John Heymach and his Lung Cancer Moon Shot team uncovered the
potential of Spectrum’s drug poziotinib to help a neglected group of
lung cancer patients and then worked closely with the company to bring
this targeted therapy to clinical trial rapidly,” said Ferran Prat,
Ph.D., J.D., MD Anderson senior vice president, research administration
and industry relations. “We are delighted to continue our collaboration
with Spectrum under this agreement, which highlights how MD Anderson
allies with private sector partners to provide new options for cancer
patients.”
Under the terms of the agreement, Spectrum has been granted a license
that includes rights to filed patents related to exon 20 as well as any
unidentified discoveries related to the use of poziotinib that may come
from Dr. Heymach’s lab at MD Anderson in the future. The filed patents,
if granted, are expected to extend the intellectual property protection
to 2037. This agreement with MD Anderson further solidifies and extends
Spectrum’s intellectual property protection for poziotinib.
About Poziotinib
Poziotinib is a novel, Epidermal Growth Factor Receptor Tyrosine Kinase
Inhibitor (EGFR TKI) that inhibits the tyrosine kinase activity of EGFR
as well as HER2 and HER4. Importantly this, in turn, leads to the
inhibition of the proliferation of tumor cells that overexpress these
receptors. Mutations or overexpression/amplification of EGFR family
receptors have been associated with a number of different cancers,
including non-small cell lung cancer (NSCLC), breast cancer, and gastric
cancer. Spectrum received exclusive license to develop, manufacture, and
commercialize worldwide excluding Korea and China from Hanmi
Pharmaceuticals. Poziotinib is currently being investigated by Spectrum
and Hanmi in several mid-stage trials in multiple solid tumor
indications.
About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals is a leading biotechnology company focused on
acquiring, developing, and commercializing drug products, with a primary
focus in hematology and oncology. Spectrum currently markets six
hematology/oncology drugs, and has an advanced stage pipeline that has
the potential to transform the company. Spectrum's strong track record
for in-licensing and acquiring differentiated drugs, and expertise in
clinical development have generated a robust, diversified, and growing
pipeline of product candidates in advanced-stage Phase 2 and Phase 3
studies. More information on Spectrum is available at www.sppirx.com.
Forward-looking statement — This press release may contain
forward-looking statements regarding future events and the future
performance of Spectrum Pharmaceuticals that involve risks and
uncertainties that could cause actual results to differ materially.These
statements are based on management's current beliefs and expectations.These statements include, but are not limited to, statements that
relate to Spectrum’s business and its future, including certain company
milestones, Spectrum's ability to identify, acquire, develop and
commercialize a broad and diverse pipeline of late-stage clinical and
commercial products, the timing and results of FDA decisions, and any
statements that relate to the intent, belief, plans or expectations of
Spectrum or its management, or that are not a statement of historical
fact.Risks that could cause actual results to differ include the
possibility that Spectrum’s existing and new drug candidates may not
prove safe or effective, the possibility that our existing and new
applications to the FDA and other regulatory agencies may not receive
approval in a timely manner or at all, the possibility that our existing
and new drug candidates, if approved, may not be more effective, safer
or more cost efficient than competing drugs, the possibility that our
efforts to acquire or in-license and develop additional drug candidates
may fail, our dependence on third parties for clinical trials,
manufacturing, distribution and quality control and other risks that are
described in further detail in the company's reports filed with the
Securities and Exchange Commission.The company does not plan to
update any such forward-looking statements and expressly disclaims any
duty to update the information contained in this press release except as
required by law.
SPECTRUM PHARMACEUTICALS, INC.® is a
registered trademark of Spectrum Pharmaceuticals, Inc and its affiliate.
REDEFINING CANCER CARE™ and the Spectrum Pharmaceuticals logos are
trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks
are the property of their respective owners.
© 2018 Spectrum Pharmaceuticals, Inc. All Rights Reserved
View source version on businesswire.com: https://www.businesswire.com/news/home/20180503005535/en/
Source: Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals, Inc.
Shiv Kapoor
Vice President,
Strategic Planning & Investor Relations
702-835-6300
InvestorRelations@sppirx.com
